ffects of Botulinum Toxin Type A on the Psychosocial Features of Myofascial Pain TMD Subjects: A Randomized Controlled Tria

Author(s)

Canales, Giancarlo De la Torre ^{[1, 2]} ; Poluha, Rodrigo Lorenzi ^[2] ; Alvarez Pinzon, Yeidi Natalia ^[1] ; Rodrigues Conti, Paulo Cesar ^[2] ; Manfredini, Daniele ^[3] ; Sanchez-Ayala, Alfonso ^[4] ; Rizzatti-Barbosa, Celia Marisa ^{[1, 5]}

Affiliation

^[1] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Prosthodont & Periodontol, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Bauru Sch Dent, Dept Prosthodont, Al Octavio Pinheiro Brisola 9-75, BR-17012901 Bauru, SP - Brazil

^[3] Univ Siena, Dept Dent, Siena - Italy

^[4] Univ Estadual Ponta Grossa, Dept Dent, Ponta Grossa, Parana - Brazil

^[5] Inga Univ Ctr, Dept Dent, Maringa, Parana - Brazil

• Document type: Journal article
• Source: JOURNAL OF ORAL & FACIAL PAIN AND HEADACHE; v. 35, n. 4, p. 288-296, FAL 2021.
• Web of Science Citations: 0

Abstract

Aims: To determine the effects of botulinum toxin type A (BoNT-A) on the psychosocial features of patients with masticatory myofascial pain (MFP). Methods: A total of 100 female subjects diagnosed with MFP were randomly assigned into five groups (n = 20 each): oral appliance (OA); saline solution (SS); and three groups with different doses of BoNT-A. Chronic pain-related disability and depressive and somatic symptoms were evaluated with the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/ TMD) Axis II instruments at baseline and after 6 months of treatment. Differences in treatment effects within and between groups were compared using chi-square test, and Characteristic Pain Intensity (CPI) was compared using two-way ANOVA. A 5% probability level was considered significant in all tests. Results: Most patients presented low pain-related disability (58%), and 6% presented severely limiting, high pain-related disability. Severe depressive and somatic symptoms were found in 61% and 65% of patients, respectively. In the within-group comparison, BoNT-A and OA significantly improved (P <.001) scores of pain-related disability and depressive and somatic symptoms after 6 months. Only the scores for painrelated disability changed significantly over time in the SS group. In the betweengroup comparison, BoNT-A and OA significantly improved (P <.05) scores of all variables at the final follow-up when compared to the SS group. No significant difference was found between the BoNT-A and OA groups (P >.05) for all assessed variables over time. Conclusion: BoNT-A was at least as effective as OA in improving pain-related disability and depressive and somatic symptoms in patients with masticatory MFP. (AU)

• FAPESP's process: 14/15863-7 - Comparison of conventional and BontA treatments in patients with myogenic temporomandibular disorders and chronic pain
• Grantee: Celia Marisa Rizzatti Barbosa
• Support Opportunities: Regular Research Grants